Neurogene Inc. (NGNE) stock
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$87.71M. At the latest close the market valued the company at $462.26M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $462.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.13
- Dividend yield
- –
- Free cash flow yield
- -18.97%
Fundamentals
- Revenue
- $0
- Net income
- -$111.11M
- EPS, diluted
- -$5.03
- Free cash flow
- -$87.71M
- Book value per share
- $9.63
- Diluted shares
- 23M
Trading
- Next earnings
- Mar 23, 2027 (estimated, before the open)
- Previous close
- $23.30
- Open
- $23.38
- Day's range
- $22.21 – $23.38
- Volume
- 278,145
- Average volume (20 days)
- 297,722
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- 52-week range
- $15.93 – $43.66
- RSI (14 days)
- 39.1
- Volatility (1 year)
- 75.8%
- Relative volume
- 0.89×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | NGNE | S&P 500 | Difference | NGNE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -4.0% | +3.4 pts | ||
| 3 months | -37.0% | -5.0% | −32.1 pts | ||
| Year to date | +12.1% | +8.2% | +3.9 pts | ||
| 1 year | +2.8% | +11.2% | −8.4 pts | ||
| 3 years | +72.4% | +68.5% | +3.9 pts | +19.9% | +19.0% |
| 5 years | -80.5% | +67.3% | −147.7 pts | -27.9% | +10.8% |
| 10 years | -92.1% | +291.6% | −383.8 pts | -22.4% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neurogene filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Neurogene
Pharmaceutical Preparations
Neurogene Inc. is a clinical-stage biotechnology company that creates genetic therapies for individuals with severe and rare neurological disorders. The company's primary focus is developing treatments using its proprietary transgene regulation platform, which controls therapeutic protein expression in targeted cells. Its leading clinical asset, NGN-401, is an adeno-associated virus gene therapy designed to treat female pediatric and adult patients suffering from Rett syndrome. The firm operates in the biopharmaceutical sector without commercialized products, directing its investigative programs toward patients and healthcare systems that manage life-threatening central nervous system illnesses.
Company profile, executives and historyNeurogene stock: common questions
What is Neurogene's stock price?
NGNE closed at $23.10 on Nov 17, 2026, down 0.86% on the day. Over the past 52 weeks it traded between $15.93 and $43.66.
What is Neurogene's market cap?
Neurogene was worth $462.26M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is NGNE's P/E ratio?
Neurogene lost money over the twelve months to Jun 30, 2026 (diluted EPS -$5.03), so it has no meaningful P/E ratio.
How much revenue does Neurogene make?
Neurogene reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Neurogene pay a dividend?
No. Neurogene has not paid a cash dividend over the last twelve months.
When does Neurogene report earnings next?
Neurogene is expected to report Q4 FY2026 results on Mar 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NGNE stock performed over the past year?
Including dividends, NGNE returned +2.8% over the past year, against +11.2% for the S&P 500.
How many NGNE shares are sold short?
6M shares were sold short at the latest FINRA report, 33.80% of the float, or 16.9 days of average trading volume.
Who are Neurogene's competitors?
Companies most similar to Neurogene by business, industry and size include KRRO, SPRB, OVID, LGVN, RNAC.
See a number that looks wrong?